Rangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported third quarter 2018 financial results and I’m pleased with our continued execution toward our vision to transform Sangamo into the premier genomic medicines company, said Sandy Macrae, CEO of Sangamo.
We’ve made strong progress across our clinical development programs and look forward to potential data readouts and updates from multiple clinical trials in coming months. We expect to complete the final steps of the acquisition of TxCell by year end, establishing our leadership in the promising field of CAR-Tregs for immunological and autoimmune diseases.
Finally, we are continuing to strengthen the leadership In September, Sangamo presented 16-week clinical results from the first two cohorts of the Phase 1/2 CHAMPIONS Study evaluating …
[Read on via official release]
Source: US SEC
View full document: